Compare CNX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | LQDA |
|---|---|---|
| Founded | 1860 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 1998 | 2020 |
| Metric | CNX | LQDA |
|---|---|---|
| Price | $36.12 | $67.04 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $35.71 | ★ $41.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | 51.81 |
| EPS | ★ 3.56 | 1.26 |
| Revenue | ★ $2,239,134,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $11.14 | $57.13 |
| P/E Ratio | ★ $10.33 | $54.86 |
| Revenue Growth | 76.76 | ★ 1031.18 |
| 52 Week Low | $29.22 | $21.15 |
| 52 Week High | $43.62 | $93.61 |
| Indicator | CNX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 40.05 |
| Support Level | $35.39 | $30.48 |
| Resistance Level | $37.58 | $92.35 |
| Average True Range (ATR) | 0.82 | 2.62 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 49.15 | 25.04 |
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.